A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

NCT01946568 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections.

Interventions

DRUG: Dalbavancin

Sponsor

Durata Therapeutics Inc., an affiliate of Allergan plc